Prix
GRAPH PAR
Questions fréquentes
Quelle est la capitalisation boursière de CEL-SCI ?
Quel est le bénéfice par action (BPA) de CEL-SCI ?
Quelles sont les évaluations des analystes et le prix cible de l'action CEL-SCI ?
Quel est l'EBITDA de CEL-SCI ?
Quel est le flux de trésorerie disponible de CEL-SCI ?
Quel est le flottant des actions de CEL-SCI ?
Finances
- Capitalisation boursière
- 46,57 M $US
- BPA (TTM)
- -0,567 $US
- Free Float
- 62,00 M
- EBITDA (TTM)
- -23,72 M $US
- Cash-flow disponible (TTM)
- -19,09 M $US
Cotation
- 1D span
- 0,711 $US0,795 $US
- 52W span
- 0,495 $US3,23 $US
Notes des analystes
L'objectif de prix est de 6,20 $US et l'action est analysée par 1 analystes.
Acheter
1
Hold
0
Vendre
0
Informations
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
- Industries
- Biotechnology
- Secteur
- Soins de santé
Identifiant
- ISIN
- US1508376076
- Ticker primaire
- CVM